143 related articles for article (PubMed ID: 7284267)
1. Structure specificity of the antipsoriatic anthrones.
Krebs A; Schaltegger H; Schaltegger A
Br J Dermatol; 1981 Aug; 105 Suppl 20():6-11. PubMed ID: 7284267
[TBL] [Abstract][Full Text] [Related]
2. Treatment of psoriasis with anthrones-chemical principles, biochemical aspects, and approaches to the design of novel derivatives.
Wiegrebe W; Müller K
Skin Pharmacol; 1995; 8(1-2):1-24. PubMed ID: 7786521
[TBL] [Abstract][Full Text] [Related]
3. [Metabolism of antipsoriatic anthrone derivatives].
Wiegrebe W; Gerber A; Kappler J; Bayerl C
Arzneimittelforschung; 1979; 29(8):1083-8. PubMed ID: 583004
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for epidermal ornithine decarboxylase induction and skin tumor promotion by anthrones.
DiGiovanni J; Kruszewski FH; Coombs MM; Bhatt TS; Pezeshk A
Carcinogenesis; 1988 Aug; 9(8):1437-43. PubMed ID: 3402040
[TBL] [Abstract][Full Text] [Related]
5. Anthralin derivatives--inhibition of 5-lipoxygenase--antipsoriatic efficacy.
Tanzer H; Braun C; Seidel M; Wiegrebe W
Arch Pharm (Weinheim); 1991 Nov; 324(11):841-6. PubMed ID: 1804060
[TBL] [Abstract][Full Text] [Related]
6. Dithranol: further investigations on the structure-activity-relationship. The new series of the 10-mono-alkyldithranol derivatives.
Schaltegger A; Brunner F; Steiger W; Krebs A
Dermatologica; 1987; 175(3):136-41. PubMed ID: 3653461
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol).
Müller K; Gürster D
Biochem Pharmacol; 1993 Nov; 46(10):1695-704. PubMed ID: 8250955
[TBL] [Abstract][Full Text] [Related]
8. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone).
Mustakallio KK; Brandt H
Acta Derm Venereol; 1984; 64(1):63-6. PubMed ID: 6203285
[TBL] [Abstract][Full Text] [Related]
9. Detection and characterization of 9-anthron-10-yl radicals formed by antipsoriatic and tumor-promoting 9-anthrones in aqueous buffers.
Hayden PJ; Chignell CF
Chem Res Toxicol; 1993; 6(2):231-7. PubMed ID: 8386561
[TBL] [Abstract][Full Text] [Related]
10. Antipsoriatic anthrones: aspects of oxygen radical formation, challenges and prospects.
Müller K
Gen Pharmacol; 1996 Dec; 27(8):1325-35. PubMed ID: 9304402
[TBL] [Abstract][Full Text] [Related]
11. Irritation, staining and antipsoriatic activity of 10-acyl analogues of anthralin.
Mustakallio KK
Br J Dermatol; 1981 Aug; 105 Suppl 20():23-7. PubMed ID: 6169361
[No Abstract] [Full Text] [Related]
12. Structure-activity relationships for the formation of secondary radicals and inhibition of keratinocyte proliferation by 9-anthrones.
Hayden PJ; Free KE; Chignell CF
Mol Pharmacol; 1994 Jul; 46(1):186-98. PubMed ID: 8058052
[TBL] [Abstract][Full Text] [Related]
13. [Antipsoriatic effect of dithranol (anthralin). 1].
Raab W
Hautarzt; 1975 Sep; 26(9):452-5. PubMed ID: 1184389
[TBL] [Abstract][Full Text] [Related]
14. [Antipsoriatic effect of dithranol (anthralin). 2].
Raab W
Hautarzt; 1975 Sep; 26(9):456-9. PubMed ID: 1102494
[No Abstract] [Full Text] [Related]
15. Anthralin and chrysarobin: a reexamination of the origins and early use.
Steger JW; Hollander A
Arch Dermatol; 1982 Sep; 118(9):625-6. PubMed ID: 7114862
[No Abstract] [Full Text] [Related]
16. Active oxygen species and structure specificity of antipsoriatic anthrones.
Müller K
Arch Pharm (Weinheim); 1988 Jul; 321(7):385-9. PubMed ID: 3219054
[No Abstract] [Full Text] [Related]
17. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals.
Müller K
Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681
[TBL] [Abstract][Full Text] [Related]
18. Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
Müller K; Reindl H; Breu K
J Med Chem; 2001 Mar; 44(5):814-21. PubMed ID: 11262091
[TBL] [Abstract][Full Text] [Related]
19. [Experiences in half-side treatment with tar additive to cignolin-salicylic-acid-white-vaseline therapy of psoriasis vulgaris].
Schulze HJ; Steigleder GK
Z Hautkr; 1984 May; 59(10):654-6. PubMed ID: 6741204
[TBL] [Abstract][Full Text] [Related]
20. [Modern psoriasis therapy].
Mahrle G
Z Hautkr; 1984 May; 59(10):645-6. PubMed ID: 6741203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
